Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Teva Pharmaceuticals Jumped Higher Today

By Brian Orelli, PhD – May 7, 2020 at 1:15PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The drugmaker had a nice turnaround quarter, but will it last?

What happened

Shares of Teva Pharmaceutical Industries (TEVA 2.84%) are up 11% at 1:50 p.m. EDT after the drugmaker announced first-quarter earnings that beat expectations.

So what

Revenue was up 5% year over year to $4.36 billion in the first quarter. For most drugmakers, 5% growth would be a slow quarter, but Teva has been struggling of late, with its multiple sclerosis drug Copaxone facing generic competition and a decline in its U.S. generic business, which resulted in revenue falling 8% year over year -- 5% in local currency terms -- in 2019.

Going from a 5% decline to a 5% gain is quite the feat. Unfortunately, some of the gain in the most recent quarter might be short-lived, since it was due to strong demand in generic and over-the-counter products and respiratory products, presumably for people stocking up and treating COVID-19, respectively.

Pills on $100 bills.

Image source: Getty Images.

Unfortunately, sales of Copaxone in the U.S. are still falling, down 5% year over year. On the non-COVID-19 plus side, U.S. sales of Austedo, which treats tardive dyskinesia and Huntington's disease chorea, were up 64% year over year to $122 million.

Teva's bottom line looked even better than the revenue growth, with the company cutting selling and marketing expenses as well as spending less on research and development, which helped boost adjusted operating income by 22% year over year. Adjusted earnings per share were up 27% to $0.76.

Now what

Even after today's move higher, shares of Teva are still down more than 20% over the last year and down more than 60% over the last three years, demonstrating just how far the drugmaker has fallen. The most recent quarter is a sign that Teva is on the turnaround track, but investors should be careful about penciling all of the first-quarter revenue gains into future quarters.

Brian Orelli and The Motley Fool have no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Teva Pharmaceutical Industries Limited Stock Quote
Teva Pharmaceutical Industries Limited
$7.96 (2.84%) $0.22

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.